Focused On-demand Library for Inhibitor of growth protein 5

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q8WYH8

UPID:
ING5_HUMAN

ALTERNATIVE NAMES:
p28ING5

ALTERNATIVE UPACC:
Q8WYH8; A8K1P3; Q53NU6; Q57Z54; Q9BS30

BACKGROUND:
The protein Inhibitor of growth protein 5, alternatively named p28ING5, is integral to the regulation of gene expression and cell cycle through its acetylation of histones H3 and H4 as part of the HBO1 and MOZ/MORF complexes. This acetylation is pivotal for chromatin remodeling, which is essential for DNA replication and transcriptional activity. Furthermore, p28ING5's role in inhibiting cell growth and enhancing apoptosis through specific pathways suggests its significance in maintaining cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Inhibitor of growth protein 5's functions offers promising avenues for therapeutic development. Given its critical role in modulating gene expression, cell growth, and apoptosis, targeting p28ING5 could provide innovative treatments for conditions characterized by aberrant cell proliferation and survival.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7776 of 8789